Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893

Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893 – NEWSnet – News… as it used to be